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Panel.	Research	in	context	
Evidence	before	this	study	
A	search	of	PubMed	for	the	terms	“multiple	myeloma”,	“histone	deacetylase	inhibitor””	for	clinical	
trials	published	between	1
st
	July	2006	and	1
st
	January	2013	was	performed	to	provide	evidence	prior	
to	 the	study.	 	This	 revealed	seven	phase	 I/II	 trials	specifically	 for	patients	with	myeloma,	 including	
investigation	of	panobinostat	as	monotherapy	and	in	combination	with	melphalan	prednisolone	and	
thalidomide.	 	 A	 number	 of	 other	HDAC	 inhibitors	were	 also	 investigated;	 however,	 none	 of	 them	
demonstrated	 clinically	 significant	 activity	 for	myeloma.	 	 	 The	PANORAMA	2	 trial	 (see	below)	 had	
commenced	before	this	study	started	enrolment.	
Added	value	of	this	study	
The	MUK-six	trial	demonstrated	the	safety	and	activity	of	panobinostat	 in	a	four	drug	combination	
for	patients	with	 relapsed	myeloma.	Since	 this	 trial	 started	 there	had	been	 further	publications	 to	
that	 described	 above.	 	 The	 included	 the	 pivotal	 phase	 III	 trial	 (PANORAMA	 2)	 of	 bortezomib	
(Velcade),	dexamethasone	plus	panobinostat	(VD-P)	versus	bortezomib	dexamethasone	and	placebo	
for	relapsed	myeloma.		A	separate	publication	of	the	predefined	sub-set	analysis	led	to	panobinostat	
approval	 in	 the	US	and	Europe.	Other	published	 trials	 included	VD-P	 for	newly	diagnosed	patients	
which	 was	 halted	 due	 to	 a	 lack	 of	 efficacy	 and	 increased	 toxicity	 (used	 bi-weekly	 intravenous	
bortezomib),	a	Phase	I/II	of	panobinostat	with	carfilzomib	and	dexamethasone	and	the	phase	I	study	
to	 determine	 the	 recommended	 dose	 of	 panobinostat	 for	 bortezomib	 combinations.	 The	
PANORAMA	 1	 phase	 II	 trial	 (VD-P)	 reported	 the	 efficacy	 of	 VD-P	 in	 patients	 with	 relapsed	 and	
bortezomib	refractory	myeloma	with	a	response	rate	of	34·5%.		However,	the	VD-P	regimen	in	the	
PANORAMA	 2	 trial	 was	 associated	 with	 significant	 gastrointestinal	 toxicity	 which	 was	 partly	
attributed	to	the	use	of	bi-weekly	intravenous	bortezomib.	The	MUK-six	study	incorporated	weekly	
subcutaneous	bortezomib	plus	low	dose	thalidomide	with	panobinostat.	The	results	described	in	this	
paper	demonstrated	high	efficacy	and	good	tolerability.		
Implications	of	all	the	available	evidence	
Panobinostat	 represents	 a	 new	 class	 of	 anti-myeloma	 therapy	 that	 has	 gained	 FDA	 and	 EMEA	
approval	 for	 patients	 following	 two	 or	 more	 prior	 lines	 of	 therapy	 including	 bortezomib	 and	 an	
immunomodulatory	agent.	This	was	based	on	the	sub-group	analysis	of	the	phase	III	PANORAMA	2	
trial.	The	MUK-six	trial	predominantly	included	patients	at	first	relapse	and	adds	to	the	evidence	that	
a	 panobinostat	 and	 proteasome	 inhibitor	 combination	 can	 be	 safely	 and	 effectively	 delivered,	
particularly	earlier	in	the	treatment	pathway	to	that	currently	indicated.	
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Abstract	(298,	maximum	300)	
Background:	Panobinostat	is	a	pan-deacetylase	inhibitor	which	in	combination	with	bortezomib	and	
dexamethasone	 is	approved	 for	patients	with	 relapsed	multiple	myeloma	 (MM).	The	MUK	six	 trial	
investigated	 panobinostat	with	 bortezomib,	 thalidomide	 and	 dexamethasone	 (VTD-P)	 for	 patients	
receiving	1-4	previous	lines	of	therapy.	
	Methods:	This	multi-centre	phase	I/II	trial	aimed	to	determine	the	maximum	tolerated	dose	(MTD)	
and	recommended	dose	(RD)	of	panobinostat	with	VTD	in	an	escalation	phase,	utilising	a	rolling	six	
design	 and	 to	 estimate	 the	 response	 rate	 at	 the	 RD	 in	 an	 expansion	 phase.	 Panobinostat	 was	
administered	days	1,	3,	5,	8,	10	and	12	with	bortezomib	1·3mg/m
2
	days	1,	8;	thalidomide	50-100mg	
daily	and	dexamethasone	20mg	days	1,	2,	8	and	9	every	21	days.	 	Patients	could	receive	up	to	16	
cycles	 of	 VTD-P	 then	 up	 to	 one	 year	 panobinostat	 maintenance.	 www.clinical	 trials.gov	
(NCT02145715),	ISRCTN59395590.	
Findings:	 57	 patients	 were	 enrolled	 with	 a	 median	 of	 one	 prior	 lines	 of	 therapy	 (80·2%	 at	 first	
relapse).	46	were	 treated	at	 the	RD	 (intention-to-treat	population).	One	dose	 limiting	 toxicity	was	
reported,	 hence	 the	 MTD	 was	 not	 reached	 and	 the	 RD	 of	 panobinostat	 was	 20mg.	 The	 overall	
response	rate	(primary	endpoint)	was	91·3%	(95%	CI	79·2%-97·6);	CR	3(6·5%),	VGPR	18	(39·1%),	PR	
21	 (45·7%),	MR	2	 (4·3%),	SD	2	 (3%)	and	was	 independent	of	prior	bortezomib.	The	overall	median	
PFS	(secondary	endpoint)	was	15·6	months	(95%	CI	13·4-20·47).	The	regimen	was	well	tolerated	with	
a	low	number	of	grade	3-4	toxicities.	The	majority	of	AEs	were	grade	1-2	with	low	rates	of	grade	3-4	
diarrhoea	and	fatigue.		
Interpretation:		This	trial	demonstrated	that	VTD-P	is	a	highly	efficacious	and	well	tolerated	regimen	
for	 patients	 with	 relapsed	 MM.	 The	 weekly	 use	 of	 sub-cutaneous	 bortezomib	 is	 likely	 to	 have	
improved	the	tolerability	compared	with	the	PANORAMA	1	trial
1
.	
Funding:	Novartis	and	Myeloma	UK	 	
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Introduction	
Proteasome	 inhibitor	 and	 immunomodulatory	 (IMiD)	 agents	 have	 become	 standard	 therapy	 for	
patients	 with	 multiple	 myeloma	 (MM).	 The	 combination	 of	 these	 two	 classes	 of	 drugs	 is	 highly	
effective	 and	 bortezomib	 (Velcade),	 thalidomide	 and	 dexamethasone	 (VTD)	 is	 commonly	 used	 as	
induction	prior	to	autologous	stem	cell	transplantation	(ASCT)
2,	3
,	and	as	an	effective	salvage	regimen	
at	 relapse	 achieving	 ≥	 partial	 response	 (PR)	 rates	 of	 63%
4
.	 Panobinostat	 (P),	 a	 pan	 histone	
deacetylase	 (HDAC)	 inhibitor	 was	 recently	 licensed	 in	 combination	 with	 bortezomib	 and	
dexamethasone	 for	 patients	 who	 have	 received	 two	 or	 more	 prior	 lines	 of	 therapy	 including	 a	
proteasome	inhibitor	and	IMiD,	based	upon	sub-group	analysis	of	the	PANORAMA	1	Phase	3	clinical	
trial
5
.	Whilst	those	treated	with	panobinostat	had	a	superior	response	rate	(≥PR	58·9%	vs	39·2%)	and	
progression-free	 survival	 (PFS)	 (12·5	 vs	 4·7	 months)	 to	 those	 receiving	 placebo,	 they	 also	
experienced	 increased	 toxicities	 particularly	 gastrointestinal	 (grade	 3-4:	 diarrhoea	 33%	 vs	 15%,	
nausea	11%	vs	1%)	and	asthenia	(grade	3-4:	26%	vs	14%).	Notably,	the	PANORAMA	1	trial
1
	utilised	
intravenous	bortezomib	administered	twice	weekly,	whereas	common	practice	uses	sub-cutaneous	
bortezomib	and	many	use	a	weekly	schedule.	
We	 therefore	designed	 the	MUK	 six	 trial	 to	 improve	 the	 tolerability	 of	 the	VD-P	 combination	 and	
investigate	 efficacy	 by	 incorporating	 low	 dose	 thalidomide	 and	 reducing	 the	 frequency	 of	
bortezomib	administration.	The	aim	of	this	phase	I/II	trial	was	to	determine	the	maximum	tolerated	
dose	(MTD)	of	panobinostat	when	given	with	VTD	(with	subcutaneous	bortezomib)	in	patients	with	
relapsed	or	relapsed	and	refractory	MM,	and	determine	the	overall	response	rate	within	16	cycles	of	
VTD-P.		
Methods	
Study	Design	and	Treatment	Schedule	
MUK	 six	was	 a	multi-centre	open	 label	 phase	 I/II	 trial	 run	 through	 the	Myeloma	UK	Clinical	 Trials	
Network,	for	patients	with	relapsed	or	relapsed/	refractory	MM	who	had	received	between	one	and	
four	 prior	 lines	of	 therapy.	 Patients	 ≥18	 years	were	eligible	with	measureable	disease,	 an	 Eastern	
Cooperative	Oncology	Group	 (ECOG)	 performance	 status	 of	 ≤2,	 neutrophils	 ≥1·0	 x	 10
9
/L,	 platelets	
≥100	x	10
9
/L,	haemoglobin	≥80g/L,	serum	creatinine	≤2·0	x	upper	limit	of	normal	and	adequate	liver	
function.	 Exclusion	 criteria	 included	 anti-myeloma	 therapy	 within	 28	 days	 of	 treatment	 (except	
dexamethasone	 160mg	 >48	 hours	 prior	 to	 treatment),	 refractory	 to	 bortezomib	 as	 per	 consensus	
criteria	 (progressed	 on	 therapy	 or	 <60	 days/	 	 achieved	 <minor	 response	 (MR)
6
),	 peripheral	
neuropathy	>grade	2	or	>grade	1	with	pain,	or	significant	cardiovascular	disease.	Following	Informed	
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consent	patients	were	registered	via	the	University	of	Leeds	Clinical	Trials	Research	Unit.	The	study	
was	approved	by	the	UK	national	ethics	committee,	Medicines	and	Healthcare	Products	Regulatory	
Agency	(MHRA)	and	registered	at	www.clinicaltrials.gov	(NCT02145715).	
The	trial	had	two	parts,	a	dose	escalation	phase	to	determine	the	MTD	and	recommended	dose	(RD)	
and	a	dose	expansion	phase	to	estimate	the	response	rate	(≥PR)	within	16	cycles	at	the	RD	(primary	
endpoint).	 Secondary	 objectives	 included	 safety	 profile	 of	 VTD-P,	 time	 to	maximal	 response,	 PFS,	
treatment	compliance	and	feasibility	of	panobinostat	maintenance.		
Patients	received	bortezomib	1·3mg/m
2
	subcutaneously	on	days	1,	8;	thalidomide	100mg	orally	daily	
(50mg	if	baseline	peripheral	neuropathy),	dexamethasone	20mg	orally	days	1,	2,	8,	9;	panobinostat	
days	1,	3,	5,	8,	10,	12	every	21	days	(Table	1).	In	the	absence	of	disease	progression	or	unacceptable	
toxicity,	patients	continued	VTD-P	for	16	cycles.	Those	eligible	 for	ASCT	were	treated	to	maximum	
response	 plus	 two	 cycles	 (minimum	 six).	 Those	 completing	 16	 cycles	 of	 VTD-P	 could	 receive	
panobinostat	monotherapy	 (at	 the	 same	 dose	 as	 the	 current	 dosing	 level	 or	 escalated	 to	 a	 level	
deemed	safe	using	the	same	schedule	as	induction)	for	up	to	one	year.	Those	undergoing	ASCT	were	
considered	 off	 study	 and	 not	 eligible	 for	 maintenance.	 Supportive	 care	 was	 as	 per	 institutional	
practice.		
A	 rolling	 six	design
7
	 (Figure	1)	was	used	 to	determine	 the	MTD	of	panobinostat	beginning	at	dose	
level	 1	 and	 dose	 limiting	 toxicities	 (DLTs)	 assessed	 during	 the	 first	 21	 days	 of	 VTD-P.	 The	 Dose	
Escalation	Review	Group	(DERG),	comprising	all	principal	investigators	and	at	least	one	independent	
member,	 reviewed	 safety	 data	 throughout	 and	 decided	 cohort	 dose	 escalations.	 The	 RD	was	 the	
highest	 dose	 level	 at	 which	 ≤1	 out	 of	 six	 patients	 experienced	 a	 DLT.	 DLTs	 were:	 total	 bilirubin	
≥grade	3	failing	to	return	to	grade	1	within	7	days,	any	other	non-haematological	toxicity	≥grade	3	
failing	to	return	to	≤grade	1	or	baseline	within	seven	days	(except	nausea,	vomiting,	diarrhoea	and	
electrolyte	imbalances),	grade	4	neutropenia	≥7	days,	grade	4	neutropenia	with	sepsis,	any	grade	4	
thrombocytopenia	failing	to	return	to	Grade	2	within	seven	days,	prolongation	of	QTc	≥Grade	3,	and	
treatment	related	death.	The	MTD	was	defined	as	the	highest	dose	level	at	which	at	least	two	of	up	
to	six	patients	experienced	a	DLT	during	the	first	cycle.	
Dose	 delays	 and	modifications	were	 as	 per	 trial	 protocol	 (see	 Supplementary	material).	 Response	
assessment	 and	 disease	 progression	 was	 performed	 locally,	 by	 Modified	 IWG	 Uniform	 Response	
Criteria
6,	8,	9
	and	also	performed	by	clinicians	independently	without	knowledge	of	the	investigator-
reported	 responses	 for	 quality	 assurance.	 Adverse	 events	 (AEs)	 and	 serious	 AEs	 were	 reported	
according	to	National	Cancer	Institute	Common	Toxicity	Criteria	for	Adverse	Events	version	4·0.	A	12	
7	
	
lead	electrocardiogram	was	performed	on	day	1	on	each	cycle	and	cytogenetic	information	obtained	
from	 CD138	 selected	 cells	 according	 to	 local	 practice.	 Adverse	 Fluorescence	 in	 situ	 hybridization	
(FISH)	 was	 defined	 as	 the	 presence	 of	 one	 or	 more	 of:	 gain(1q),	 del(p17q),	 t(4;14),	 t(14;16)	 and	
t(14;20)
10
.	
Statistical	Analysis	
For	the	expansion	phase,	forty	two	patients,	 including	six	patients	from	the	escalation	phase,	were	
deemed	sufficient	 to	estimate	activity	of	 the	RD	 (≥PR).	This	gave	80%	power	 to	observe	at	 least	a	
78%	response	rate	and	rule	out	a	rate	of	<63%	at	the	1-sided	10%	significance	level	using	A’Hern’s	
exact	 single	 stage	 design
11
.	 The	 lower	 limit	 response	 rate	 of	 63%	 was	 based	 on	 data	 for	 VTD
4
	
assuming	a	heterogeneous	population	with	1-4	prior	lines.		
Safety	data	 is	for	all	 that	received	at	 least	one	dose	of	any	trial	treatment	(safety	population).	The	
primary	 analysis	 population	 to	 determine	 the	RD	of	 panobinostat	was	 initially	 defined	 as	 patients	
receiving	 ≥1	 cycle,	 missing	 no	 more	 than	 1	 dose	 of	 bortezomib,	 3	 of	 thalidomide,	 1	 of	
dexamethasone	or	1	of	panobinostat	(evaluable	population).	However	this	was	felt	not	to	reflect	an	
overall	realistic	estimate	of	activity	in	this	population.	Before	analysis	and	in	discussion	with	the	Trial	
Steering	Committee,	the	primary	analysis	population	was	revised	to	the	ITT	population	(received	≥1	
dose	of	panobinostat	at	the	RD).	This	population	was	used	for	all	efficacy	and	compliance	endpoints.	
The	RD	cohort	includes	all	patients	registered	to	escalation	or	expansion	phases	and	treated	at	the	
RD	of	panobinostat.		
There	 was	 no	 formal	 statistical	 testing.	 Percentages	 were	 calculated	 using	 the	 total	 number	 of	
patients	in	the	appropriate	population	as	the	denominator.	Confidence	intervals	(CI)	were	calculated	
using	 the	 Clopper-Pearson	 method,	 PFS	 and	 time	 to	 maximum	 response	 used	 the	 Kaplan	 Meier	
method.	 ASCT	 patients	 were	 censored	 at	 time	 of	 ASCT	 for	 primary	 PFS	 analysis	 and	 sensitivity	
analyses	performed.	
Role	of	Funding	Source	
The	 funder,	 Myeloma	 UK,	 conducted	 independent	 review	 of	 the	 study	 proposal,	 attended	 Trial	
Management	Group	and	DERG	meetings.	Novartis	provided	panobinostat,	funding	to	Myeloma	UK,	
attended	DERG	meetings	to	provide	safety	updates	on	panobinostat,	but	had	no	involvement	in	the	
design,	conduct,	analysis	or	interpretation.	The	Sponsor	had	no	involvement	in	the	design,	conduct,	
analysis	or	 interpretation	of	the	study.	The	corresponding	author	had	full	access	to	the	data	and	is	
responsible	for	manuscript	submission.	
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Results	
The	trial	registered	67	patients	across	four	sites	between	31
st
	January	2013	and	30
th
	October	2014.	
57	eligible	patients	that	received	≥	one	dose	of	drug	were	included	in	the	safety	population.	Of	the	
ten	patients	not	eligible,	nine	did	not	meet	the	entry	criteria	and	one	withdrew	consent.	The	dose	
escalation	 phase	 comprised	 16	 patients.	 Seven	 were	 registered	 to	 the	 10mg	 cohort	 with	 six	
evaluable	 for	 DLTs;	 three	 patients	 registered	 to	 the	 15mg	 cohort,	 all	 evaluable	 for	 DLTs;	 and	 six	
patients	 registered	 to	 the	 20mg	 cohort	 and	 evaluable	 for	 DLTs	 (Figure	 2).	 There	 was	 one	 DLT	 of	
grade	 3	 hyponatremia	 (unrelated	 to	 study	 drugs,	 due	 to	 high	 paraprotein)	 reported	 at	 20mg	 of	
panobinostat	and	consequently	the	MTD	of	panobinostat	was	not	reached.	The	RD	of	panobinostat	
was	taken	at	20mg.	
The	 ITT	 population	 comprised	 46	 patients	 treated	 at	 the	 RD,	 and	 the	 evaluable	 population	 39	
patients.	 Baseline	 demographics	 are	 in	 Table	 2.	 The	 median	 number	 of	 prior	 therapies	 was	 one	
(range	1-4)	and	64·3%	had	received	prior	ASCT,	80·4%	had	received	only	one	prior	therapy.	66·1%	of	
patients	had	prior	bortezomib,	60·7%	prior	Immunomodulatory	agent	(IMiD),	and	21·4%	≥	two	prior	
lines	of	therapy	including	bortezomib	and	an	IMiD	(known	as	the	European	Medicines	Agency	(EMA)	
approval	population).	Patients	 received	a	median	of	10	 cycles	of	 treatment	and	24	patients	 (51%)	
came	 off	 study	 following	 a	median	 of	 8	 (range	 6-16)	 cycles	 to	 proceed	 to	 ASCT.	 Twenty	 (35·1%)	
patients	 completed	 16	 cycles	 and	 15	 (26·3%)	 received	 panobinostat	 maintenance.	 Nine	 (15·8%)	
stopped	study	treatment	due	to	disease	progression,	one	died	on	study	due	to	an	unrelated	event	
(sickle	 cell	 crisis)	 and	 3	 (5·3%)	 withdrew	 consent	 due	 to	 toxicity.	 At	 the	 time	 of	 final	 analysis	 six	
patients	 had	 died:	 two	 due	 to	 MM,	 two	 due	 to	 unspecified	 abdominal	 causes,	 one	 due	 to	
cerebrovascular	disease	and	another	from	a	secondary	malignancy.	
The	overall	 response	 rate	 for	patients	 treated	at	 the	RD	 (ITT	population	n=46)	was	91·3%	 (95%	CI	
79·2-97·6);	Table	3	 shows	breakdown	by	maximum	response	and	varying	subgroups.	The	depth	of	
response	was	higher	for	those	treated	at	first	relapse	than	those	at	later	stages	(≥VGPR:	1	prior	line,	
54·7%	 (n=37)	 vs	 >1	 prior	 line,	 11·1%	 (n=9)),	 and	 lower	 for	 those	 in	 the	 EMA	 approval	 population	
(≥VGPR	 12·5%	 (n=8)	 vs	 52·6%	 (n=38).	 Responses	 were	 similar	 according	 to	 prior	 bortezomib	
exposure	 (≥VGPR:	 	 45·5%	 (n=33)	 vs	 46·2%	 (n=13))	 and	 slightly	 lower	with	 prior	 IMiD	 exposure	 (≥	
VGPR	37·5%	(n=24)	vs	54·5%	(n=22)).	VGPR	and	above	rates	were	slightly	lower	for	those	with	one	or	
more	adverse	 FISH	 lesions
10
	 (42·9%	adverse	 FISH	 (n=21)	 vs	52·2%	Standard	FISH	 (n=23));	 however	
the	overall	response	rate	was	similar.	Only	two	patients	had	a	17p	deletion	and	both	responded	(1	
9	
	
PR,	1	VGPR).	The	 independently	assessed	responses	were	very	similar	 to	 the	 investigator	assessed	
responses.	 The	 median	 time	 to	 maximal	 response	 was	 2·46	 months	 (95%	 CI	 1·91-3·52)	 with	
responses	deepening	with	treatment	duration	(median	time	to	≥	VGPR	3·71	months;	median	time	to	
MR/PR	1·84	months).	
Progression-free	survival	curves	are	displayed	in	Figure	3.	Median	PFS	was	15·6	months	(95%	CI	13·4-
20·47)	 and	 12	month	 PFS	 was	 75·4%	 (95%	 CI	 56·7-86·8).	 PFS	 at	 12	months	 was	 91·3%	 for	 those	
patients	 who	 underwent	 ASCT	 (n=24,	median	 not	 yet	 reached)	 and	 66·1%	 for	 those	 that	 did	 not	
(n=22,	median	PFS	14·1	months	(95%	CI	7·0-16·10)).	Median	overall	survival	 (OS)	was	not	reached,	
with	a	median	follow-up	of	15·0	months.	
For	those	treated	at	the	RD,	the	actual	mean	panobinostat	dose	administered	across	all	cycles	was	
17·2mg	 (86·2%	of	 the	 20mg	 planned	 dose).	 Nineteen	 (41·3%)	 patients	 required	 at	 least	 one	 dose	
reduction	and	 five	 (10·9%)	 received	at	 least	one	cycle	without	panobinostat.	The	reasons	 for	dose	
reductions	 were:	 ≥grade	 2	 non-haematological	 toxicity	 (8/19,	 42·1%),	 AST/ALT	 levels	 ≥	 5	 x	 upper	
limit	 (3/19,	 15·8%),	 grade	 3-4	 haematological	 toxicity	 (5/19,	 26·3%),	 other	 (10/19,	 52·6%).	 Seven	
(15·2%)	patients	received	at	 least	one	dose	reduction	due	to	a	GI	toxicity.	Twenty	(43·5%)	patients	
required	 a	 dose	 reduction	 in	 thalidomide	 and	 this	 was	 proportionally	 more	 for	 those	 starting	 at	
100mg	thalidomide	(10,	52·6%)	compared	with	those	starting	at	50mg	(10,	37%).	Overall,	the	actual	
overall	dose	administered	was	79·3%	of	that	intended	with	those	starting	at	50mg	receiving	a	mean	
dose	of	41·4mg	and	those	at	100mg	received	a	mean	of	72·9mg.	Only	six	(13·3%)	patients	required	a	
dexamethasone	 dose	 reduction	 with	 a	 mean	 dose	 of	 18·7mg	 (90·4%	 of	 the	 intended	 20mg)	
administered.	 Bortezomib	 compliance	 was	 good	 with	 only	 five	 (10·9%)	 patients	 requiring	 a	 dose	
reduction.	A	mean	of	1·2	mg/m
2
	(95·0%	of	the	intended	1·3mg	/m
2
)	was	administered.	
Adverse	 events	 reported	 in	 ≥10%	of	 patients	 irrespective	 of	 causality	 are	 detailed	 in	 Table	 4.	 The	
commonest	 ≥grade	 3	 toxicities	 in	 the	 safety	 population	 (n=57)	 were	 neutrophil	 count	 reduced	
(26·4%),	 hypophosphatemia	 (19·3%),	 platelet	 count	 decreased	 (14·1%),	 raised	 alanine	
aminotransferase	(7·0%),	diarrhoea	(7·0%,	grade	3	only)	and	upper	respiratory	tract	infection	(7·0%).	
The	 commonest	 all	 grade	 toxicities	 were	 fatigue	 (89·5%)	 peripheral	 sensory	 neuropathy	 (77·2%),	
diarrhoea	 (66·7%),	 constipation	 (63·2%),	 bone	 pain	 (61·4%)	 and	 nausea	 (45·6%);	 however,	 these	
were	predominantly	grade	1-2.		
Fifteen	patients	received	panobinostat	maintenance	following	completion	of	16	cycles	of	VTD-P,	of	
which	four	are	ongoing	at	the	time	of	analysis.	The	mean	number	of	cycles	received	at	the	time	of	
the	 analysis	 was	 9·3	 (range	 3-16).	 four	 patients	 (26·7%)	 completed	 one	 year	 of	 maintenance,	 six	
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stopped	 due	 to	 disease	 progression	 and	 one	 withdrew	 consent	 for	 further	 treatment	 due	 to	
predominantly	 gastrointestinal	 toxicity.	 Four	 patients	 reduced	 the	 panobinostat	 dose	 due	 to	
diarrhoea;	no	dose	reductions	occurred	after	cycle	4.	The	mean	dose	of	panobinostat	received	was	
16·5mg.	
Discussion	
This	phase	 I/II	 study	demonstrated	 that	panobinostat	 at	 20mg	 can	be	 safely	 given	 in	 combination	
with	VTD	for	patients	with	relapsed	MM.	Response	rates	were	high	(ORR	91%,	≥	VGPR	45·6%)	and	
similar	according	to	prior	bortezomib	exposure,	suggesting	effectiveness	of	this	as	a	“bortezomib	re-
treat”	 regimen.	As	expected,	 those	 treated	earlier	 in	 their	disease	 responded	better	 than	 those	at	
later	relapse	(≥VGPR	rates:	54·1%	(1	prior	line)	vs	11·1%	(≥2	prior	lines)).	Whilst	the	numbers	in	the	
≥2	 prior	 lines	 sub-group	 are	 small	 (n=8),	 it	 is	 interesting	 that	 75%	 of	 patients	 achieved	 ≥PR	
(PANORAMA	1	trial	same	sub-group	analysis	≥PR	58·9%	(n=73)
5
).	The	VGPR	rates	reported	here	were	
high;	however	the	number	of	CRs	achieved	(8.1%	for	1
st
	relapse)	was	lower	than	expected	(MMVAR-
IFM	trial	28%
12
).	This	may	be	due	to	a	low	number	of	bone	marrow	biopsies	performed	to	confirm	
CR,	and	a	significant	proportion	of	patients	coming	off	study	early	(median	cycle	6	out	of	a	possible	
16)	 for	ASCT.	As	 two	doses	of	 s.c.	 bortezomib	were	administered	per	 cycle,	 the	 tolerability	of	 the	
regimen	 was	 good	 and	 patients	 remained	 on	 study	 deepening	 response	 with	 time,	 in	 fact	 one	
patient	 achieved	 a	 VGPR	 after	 cycle	 11.	 Treatment	 was	 well	 tolerated	 with	 only	 two	 patients	
withdrawing	 consent	 due	 to	 toxicity	 (PANORAMA	 1,	 36%	 patients	 discontinued	 due	 to	 adverse	
events
1
).	 The	majority	 of	 AEs	 were	 grade	 1-2	 with	 low	 rates	 of	 grade	 3-4	 diarrhoea	 and	 fatigue.	
Panobinostat	 maintenance	 was	 well	 tolerated	 and	 feasible.	 Fifteen	 patients	 commenced	
maintenance	 with	 four	 ongoing	 at	 the	 time	 of	 this	 report.	 Four	 patients	 completed	 16	 cycles	 of	
maintenance,	 but	 the	 median	 dose	 delivered	 fell	 with	 duration	 (20mg	 at	 start	 of	 maintenance,	
12·5mg	at	cycle	16)	mainly	due	to	diarrhoea.	The	impact	of	maintenance	cannot	be	determined	due	
to	a	lack	of	comparator.	
Whilst	the	outcomes	for	patients	with	relapsed	MM	continue	to	improve
13
,	there	is	a	need	for	new	
effective	classes	of	drugs.	HDAC	inhibitors	have	alternate	mechanisms	of	cytotoxicity	to	proteasome	
inhibitors	and	 IMiDs	and	demonstrate	synergy	 in	pre-clinical	models
14
.	The	phase	 III	PANORAMA	1	
study	 demonstrated	 an	 improvement	 in	 PFS	 for	 those	 treated	 with	 panobinostat,	 particularly	
patients	with	two	or	more	prior	lines	of	therapy	including	a	proteasome	inhibitor	and	IMiD
1,	5
.	These	
patients	otherwise	have	a	poor	prognosis	with	a	median	PFS	of	4·7	months	with	VD.	However,	the	
tolerability	of	the	VD-P	regimen	could	be	improved.	This	study	suggests	that	the	4	drug	combination	
was	 tolerable	 with	 a	 lower	 proportion	 of	 grade	 3-4	 toxicities	 than	 the	 PANORAMA	 1	 study,	
11	
	
particularly	diarrhoea	and	fatigue.	It	is	likely	that	the	weekly	s.c.	administration	of	bortezomib	with	
only	 2	 doses	 per	 3	 weeks	 improved	 the	 overall	 toxicity	 profile.	 The	 incorporation	 of	 low	 dose	
thalidomide	 (≤100mg)	 is	 likely	 to	 have	 increased	 the	 efficacy	 and	 may	 in	 fact	 have	 reduced	 the	
incidence	 of	 diarrhoea.	 The	 rate	 of	 grade	 3-4	 peripheral	 neuropathy	 was	 low	 reflecting	 a	 low	
intensity	bortezomib	and	thalidomide	schedule.	
The	primary	endpoint	was	planned	to	be	compared	to	a	study	of	patients	treated	with	VTD	that	had	
at	least	two	prior	lines	of	therapy
4
.	This	was	no	longer	appropriate	as	80·4%	of	patients	enrolled	had	
one	prior	 line	of	therapy.	A	more	appropriate	comparator	would	be	the	MMVAR-IFM	2005-04	trial	
comparing	VTD	with	TD	for	patients	at	first	relapse	following	previous	ASCT
12
	which	reported	an	ORR	
for	VTD	of	87%,	≥VGPR	56%,	(MUK	six	1
st
	relapse:	ORR	94·6%,	≥VGPR	54·1%).	However	this	group	of	
patients	 were	 better	 as	 all	 were	 bortezomib	 naïve,	 none	 refractory	 to	 therapy,	 all	 had	 received	
previous	ASCT	and	received	a	total	of	48	doses	of	V.	 	This	compared	to	58·7%	receiving	prior	ASCT	
and	a	total	of	32	doses	of	V	given	in	MUK	six.	
Panobinostat	has	also	been	combined	with	carfilzomib	 in	a	 four	weekly	schedule	with	a	 rest	week	
between	the	two	weeks	of	panobinostat
15
.	This	schedule	was	well	tolerated	and	resulted	in	an	ORR	
of	 67%	 in	 a	more	 heavily	 pre-treated	 population	 (median	 of	 five	 prior	 lines).	However,	whilst	 the	
MTD	was	determined	to	be	30mg,	the	authors	recommended	the	20mg	dose	should	be	investigated	
further.	 In	 comparison	 to	 many	 other	 new	 treatments,	 VTD	 is	 comparatively	 cost-effective	
particularly	 as	bortezomib	will	 soon	be	off	 patent.	 Therefore	 the	VTD-P	 regimen	 is	 likely	 to	be	 an	
attractive	 treatment	option	 in	a	 real	world	setting	where	 funding	 is	 rationed.	Other	DACs	are	also	
under	investigation.	Vorinostat	with	bortezomib	was	investigated	in	a	randomised	phase	III	trial	for	
relapsed	MM.	The	improvement	in	PFS	for	the	combination	over	bortezomib	monotherapy	was	not	
clinically	 relevant
16
.	 Early	 data	 for	 Ricolinostat	 (a	 selective	 HDAC	 6	 inhibitor)	 in	 combination	with	
bortezomib	suggested	efficacy	and	tolerability
17
.	
As	 the	treatment	paradigm	for	MM	continues	 to	evolve	and	new	classes	of	drugs	are	approved,	 it	
remains	 crucial	 to	 maintain	 long	 term	 tolerability	 with	 multi-agent	 regimens.	 The	 MUK	 six	 trial	
demonstrated	 an	 efficacious	 and	 well	 tolerated	 four	 drug	 schedule	 for	 a	 new	 class	 of	 agent,	
panobinostat	in	combination	with	VTD	for	patients	with	relapsed	MM.		
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Table	1:	Dose	escalation	and	schedule	
Dose  
cohort 
Bortezomib (s/c) 
Days 1 and 8 
Thalidomide 
(oral) 
Days 1 - 21 
Dexamethasone 
(oral)  
Days 1, 2, 8 and 9 
Panobinostat (oral) 
Days 1, 3, 5, 8, 10 and 
12 
1 1·3 mg/m
2
 100 mg/day* 20 mg 10 mg 
2 1·3 mg/m
2 
100 mg/day* 20 mg 15 mg 
3 1·3 mg/m
2 
100 mg/day* 20 mg 20 mg 
*50mg	for	those	with	baseline	neuropathy	
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Table	2	Baseline	demographics	and	treatment	characteristics	
Demographic	 All	 patients	 (safety	 population	
N=57)	
n	(%)	
Intent-to-treat	 population	
(N=46)	
n	(%)	
Median		Age/	yrs 
 
	 	
Median (Range)	 61·0 (41·0, 76·0) 60·5 (41·0, 76·0) 
Sex   
   Male 34 (59·6) 27 (58·7) 
   Female 23 (40·4) 19 (41·3) 
ECOG	Performance	Status   
   0 26 (45·6) 22 (47·8) 
   1 26 (45·6) 21 (45·7) 
   2 3 (5·3) 2 (4·3) 
Missing 2 (3·5) 1 (2·2) 
ISS   
   1 32 (56·1) 28 (60·9) 
   2 16 (28·1) 13 (28·3) 
   3 6 (10·5) 3 (6·5) 
Missing 3 (5·3) 2 (4·3) 
Prior	Lines	   
1 43 (75·4) 37 (80·4) 
15	
	
2 6 (10·5) 5 (10·9) 
3 5 (8·8) 1 (2·2) 
4 
3 (5·3) 3 (6·5) 
Prior	bortezomib	
  
No 19 (33·3) 13 (28·3) 
Yes 38 (66·7) 33 (71·7) 
Prior	IMiD	
  
No 23 (40·4) 22 (47·8) 
Yes 34 (59·6) 24 (52·2) 
EMA	population*	
  
No 45 (78·9) 38 (82·6) 
Yes 12 (21·1) 8 (17·4) 
Time	 from	diagnosis	 to	 registration	
(months)	)include	partial	dates**	
  
Mean (SD) 43·8 (28·43) 40·6 (28·36) 
Median (Range) 33·2 (11·8, 148·0) 30·8 (11·8, 148·0) 
Missing 10 8 
*  at least 2 prior lines of therapy including bortezomib and an IMiD 
** missing days and months are set to 15 and 06 respectively 
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Table	3:	Best	Responses	
	 ORR	≥PR	
n	(%)	
≥	VGPR	
n	(%)	
CR	
n	(%)	
VGPR	
n	(%)	
PR	
n	(%)	
MR	
n	(%)	
SD	or	NC	
n	(%)	
ITT	
(N=46)	
42	(91·3)	 21	(45·7)	 3	(6·5)	 18	(39·1)	 21	(45·7)	 2	(4·3)	 2	(4·3)	
1	prior	line	
(N=37)	
35	(94·6)	 20	(54·1)	 3	(8·1)	 17	(45·9)	 15	(40·5)	 0	(0·0)	 0	(0·0)	
>1	 prior	
lines	(n=9)	
7	(77·8)	 1	(11·1)	 0	(0·0)	 1	(11·1)	 6	(66·7)	 2	(22·2)	 0	(0·0)	
Prior	 BZ	
(N=33)	
30	(90·9)	 15	(45·5)	 2	(6·1)	 13	(39·4)	 15	(45·5)	 2	(6·1)	 1	(3·0)	
BZ	 naïve	
(N=13)	
12	(92·3)	 6	(46·2)	 1	(7·7)	 5	(38·5)	 6	(46·2)	 0	(0·0)	 1	(7·7)	
Prior	 IMiD	
(N=24)	
21	(87·5)	 9	(37·5)	 1	(4·2)	 8	(33·3)	 12	(50·0)	 2	(8·3)	 1	(4·2)	
IMid	 naïve	
(N=22)	
21	(95·5)	 12	(54·5)	 2	(9·1)	 10	(45·5)	 9	(40·9)	 0	(0·0)	 1	(4·5)	
EMA	
population	
(N=8)	
6	(75·0)	 1	(12·5)	 0	(0·0)	 1	(12·5)	 5	(62·5)	
	
2	(25·0)	 0	(0·0)	
Standard	
FISH	
(N=23)	
21	(91·3)	 12	(52·2)	 2	(8·7)	 10	(43·5)	 9	(39·1)	 1	(4·3)	 1	(4·3)	
Adverse	
FISH	
(N=21)	
20	(95·2)	 9	(42·9)	 1	(4·8)	 8	(38·1)	 11	(52·4)	 1	(4·8)	 0	(0·0)	
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Table	4:	Adverse	Events	(safety	population	n=57)	
	
Adverse	Event	
	
Total	(n,	%)	 	Grade	 1	 (n,	
%)	
Grade	 2	 (n,	
%)	
Grade	 3	 (n,	
%)	
Grade	 4	 (n,	
%)	
Fatigue	 51	(89·5)	 36	(63·2)	 13	(22·8)	 2	(3·5)	 	
Peripheral	sensory	
neuropathy	
44	(77·2)	 41	(71·9)	 3	(5·3)	 	 	
Diarrhoea	 38	(66·7)	 26	(45·6)	 7	(12·3)	 4	(7)	 	
Constipation	 36	(63·2)	 30	(52·6)	 6	(10·5)	 	 	
Bone	pain	 35	(61·4)	 26	(45·6)	 7	(12·3)	 	 	
Nausea	 26	(45·6)	 23	(40·4)	 3	(5·3)	 	 	
Back	pain	 25	(43·9)	 18	(31·6)	 7	(12·3)	 	 	
Upper	respiratory	
infection	
24	(42·1)	 16	(28·1)	 2	(3·5)	 4	(7)	 	
Edema	limbs	 23	(40·4)	 22	(38·6)	 1	(1·8)	 	 	
Neutrophil	count	
decreased	
22	(38·6)	 4	(7)	 3	(5·3)	 12	(21·1)	 3	(5·3)	
Tremor	 22	(38·6)	 19	(33·3)	 2	(3·5)	 1	(1·8)	 	
Anemia	 21	(36·8)	 7	(12·3)	 11	(19·3)	 3	(5·3)	 	
Dyspnea	 20	(35·1)	 15	(26·3)	 3	(5·3)	 1	(1·8)	 	
Hypophosphatemia	 19	(33·3)	 1	(1·8)	 7	(12·3)	 10	(17·5)	 1	(1·8)	
Platelet	count	
decreased	
19	(33·3)	 6	(10·5)	 5	(8·8)	 3	(5·3)	 5	(8·8)	
Somnolence	 19	(33·3)	 19	(33·3)	 	 	 	
Dizziness	 18	(31·6)	 12	(21·1)	 5	(8·8)	 	 	
Creatinine	
increased	
16	(28·1)	 10	(17·5)	 5	(8·8)	 1	(1·8)	 	
	Myalgia	 15	(26·3)	 14	(24·6)	 1	(1·8)	 	 	
Cough	 14	(24·6)	 14	(24·6)	 	 	 	
Rash	maculo-
papular	
14	(24·6)	 11	(19·3)	 3	(5·3)	 	 	
Anorexia	 12	(21·1)	 11	(19·3)	 1	(1·8)	 	 	
Dysgeusia	 11	(19·3)	 10	(17·5)	 1	(1·8)	 	 	
18	
	
Fever	 11	(19·3)	 6	(10·5)	 3	(5·3)	 1	(1·8)	 	
Hypocalcemia	 11	(19·3)	 7	(12·3)	 4	(7)	 	 	
Vomiting	 10	(17·5)	 5	(8·8)	 3	(5·3)	 2	(3·5)	 	
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Figure	1:	Rolling	6	design		
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Figure	2:	consort	diagram	
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Figure	3:	Kaplan-Meier	plots	of	PFS	for	(A)	ITT	population,	(B)	split	according	to	recieved	ASCT	or	not	
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